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Abstract
The Val34Leu polymorphism in the A subunit of blood
coagulation factor XIII (FXIII-A) is located in the acti-
vation peptide, just three amino acids upstream of the
thrombin cleavage site. The Val™Leu replacement
accelerates the rate of the proteolytic activation of
FXIII and it seems to provide protection against myo-
cardial infarction. Methods available for the assess-
ment of the FXIII-A Val34Leu polymorphism are rather
time-consuming, laborious and not easily applicable
for large-scale studies. In this study a new method
based on real-time PCR with fluorescence resonance
energy transfer (FRET) detection and melting curve
analysis was developed. The rapid, simple method
was adapted to the widely used real-time PCR instru-
ment, LightCycler (Roche Diagnostics). The results
showed 100% coincidence with those obtained by the
traditional PCR-restriction fragment length polymor-
phism (RFLP) assay and fluorescent DNA sequencing.
Using this method, an allele frequency of 24.2% was
obtained (ns113), which well agrees with the allele
frequency obtained by PCR-RFLP on a different group
of the same ethnic Hungarian population (25.9%).
Keywords: factor XIII; fluorescence resonance energy
transfer; gene polymorphism; real-time PCR.
Blood coagulation factor XIII (FXIII) is a zymogen of
tetrameric structure (A2B2); it consists of two poten-
tially active A subunits (FXIII-A) and two carrier/pro-
tective B subunits (FXIII-B). FXIII is converted into an
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active transglutaminase (FXIIIa) by the concerted
action of thrombin and Ca2q. Thrombin cleaves off an
activation peptide of 37 amino acid residues from the
N-terminus of FXIII-A, then in the presence of Ca2q
FXIII-B dissociates and FXIII-A assumes an enzymati-
cally active configuration. FXIIIa catalyzes the forma-
tion of glutaminyl-lysyl bonds between fibrin chains
and covalently cross-links a2-plasmin inhibitor to
fibrin. In this way FXIIIa mechanically stabilizes the
fibrin clot and increases its resistance to fibrinolysis
wfor reviews, see (1–3)x. FXIII-A is a rather polymor-
phic protein; five common polymorphisms resulting
in amino acid replacement have been described (3).
One of these polymorphisms, a G™T substitution in
exon 2 resulting in Val™Leu replacement at position
34 (4) (GenBank accession no. M21986), has attracted
a lot of interest in the last couple of years. The fre-
quency of the Leu34 allele among Caucasians is
around 25%, it is much lower in blacks and Asian Indi-
ans and extremely rare in the Japanese population.
The site of the polymorphism is just three amino
acids upstream of the thrombin cleavage site and it
has been shown that the cleavage of the Leu34 vari-
ant, and consequently the activation of Leu34 FXIII,
occurs significantly faster than that of the wild-type
factor (5–7). In the first studies a protective effect of
the Leu34 allele against myocardial infarction (8) and
venous thrombosis (9) was reported. In follow-up
studies both confirmatory and contradictory results
were demonstrated wfor a review, see (3)x and further
large-scale studies seem to be required for clarifying
the conditions under which the Leu34 allele exerts its
protective effect.
In the epidemiological studies carried out so far,
polymerase chain reaction (PCR) combined with sin-
gle-stranded conformation polymorphism (SSCP)
(8, 10) or restriction fragment length polymorphism
(RFLP) (5, 11) detection, allele-specific PCR (12) or
solid phase mini-sequencing (13) were used to distin-
guish among different Val34Leu FXIII-A genotypes.
These methods are rather time-consuming, laborious
and not easily applicable for large-scale studies. Here,
we present an alternative approach based on real-
time PCR with fluorescence resonance energy trans-
fer (FRET) detection and melting curve analysis. This
rapid, simple method was adapted to the widely used
real-time PCR instrument, LightCycler (Roche Diag-
nostics, Mannheim, Germany).
DNA was isolated from citrated whole blood of 113
unrelated subjects w68 wild-type (V/V), 36 heterozy-
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Table 1 Primers and probes used for genotyping the FXIII-
A Val34Leu polymorphism.
Primers/ Sequence
probes
Forward 59-GAC CTT GTA AAG TCA AAA ATG TC-39
primer
Reverse 59-AA-GGG-GGG-TAT-GCT-CAT-39
primer
Sensor 59-G-CAC-A*AC-GCC-CTG-AAG-C-39FLa,b
Anchor 59-LC Red640-C-CAC-TGT-GGG-CAG-GTC-ATC-
TTC-C-39-Pa
aFL, fluorescein; P, phosphorylated, bthe site of the mutation
is underlined; in the sensor a mismatch (C™A) was intro-
duced at the position labeled with asterisk.
Figure 1 Representative derivative melting curves wyd(F2)/
dT vs. Tx of the three FXIII-A Val34Leu genotypes. Thick solid
line, V/V; dotted line, V/L; dashed line, L/L; thin solid line, no
template control.
gote (V/L), 9 homozygote (L/L)x using the MagNA Pure
LC Instrument (Roche Diagnostics). Primers and
probes were synthesized by TIB MOLBIOL (Berlin,
Germany). The nucleotide compositions of primers
and probes are shown in Table 1. The detection probe
(sensor) labeled with fluorescein at the 39 end covers
the polymorphic site. A C™A mismatch was intro-
duced in the sensor to decrease the melting temper-
ature for both alleles. The adjacent anchor probe was
59 labeled with LC Red640 dye and the 39 end was
phosphorylated to prevent probe elongation by Taq
polymerase. The gap between the two probes is a sin-
gle nucleotide. If the probes lie adjacent to each other
on a DNA strand, fluorescence resonance energy
transfer occurs and the fluorescence of LC Red640 is
detected by the fluorimeter component of LightCycler.
PCR reactions were performed in the LightCycler
glass capillaries in a final volume of 21 ml containing
150 ng of genomic DNA, 0.19 mmol/l of each primer,
0.57 mmol/l of anchor probe, 0.38 mmol/l of sensor
probe, 2 U Taq DNA polymerase (Roche), 2 ml of 10=
concentrated PCR reaction buffer (Roche), 42.9 ml/l
dimethyl sulfoxide (Sigma; St. Louis, MO, USA),
0.48 mmol/l of each dNTP (Roche), plus an extra
2.86 mmol/l of MgCl2 (Roche). One sample without
DNA, as a negative control, was included in all assay
series. Cycling conditions were as follows: initial
denaturation at 958C for 30 s, 60 cycles of denatura-
tion at 948C for 0 s, annealing at 508C for 5 s and
extension at 728C for 10 s. Melting curve analysis con-
sisted of one cycle at 948C for 15 s and at 358C for
15 s, followed by increasing the temperature to 708C
at a 0.18C/s ramping rate. The fluorescent signal of LC
Red640 was monitored continuously during the tem-
perature ramp and the results were transformed to
derivative melting curves. Melting peak analysis eas-
ily discriminated the three different FXIII-A Val34Leu
genotypes: melting temperature (Tm) for the wild-type
(Val/Val) was at 56.48C, while Tm for the homozygote
mutant (Leu/Leu) was at 47.58C; heterozygotes dem-
onstrated both peaks (Figure 1).
One hundred and thirteen individual DNA prepara-
tions from a sample pool were tested by the method
described above and by PCR-RFLP according to Bal-
ogh et al. (5). The results were in 100% concordance.
The frequency of the Leu34 allele was 24.2% (95% CI:
16.3–32.1%), which agrees well with the allele fre-
quency obtained by PCR-RFLP on a different group of
the same ethnic Hungarian population (25.9%; 95% CI:
22.3–29.5%) (5), and with the data reported for other
Caucasian populations (14). Fifty randomly selected
DNA samples (26 wild-type, 19 heterozygous and 5
homozygous for the FXIII-A Val34Leu polymorphism)
were also evaluated by fluorescent DNA sequencing
using the BigDye Terminator Reaction kit on an ABI
310 Genetic Analyzer (Applied Biosystems; Weiter-
stadt, Germany); again 100% concordance was
observed. To test the reproducibility of the assay,
DNA samples of all three genotypes were retested on
at least 20 different occasions. All results were con-
sistent. Since the introduction of the assay, 500
patients’ samples have been tested for the Val34Leu
polymorphism in our laboratory, and in all cases a
clear discrimination among the different FXIII-A
Val34Leu genotypes has been observed.
Most recently, two real-time PCRmethods, apyrase-
mediated allele-specific primer extension (15) and 59
nuclease assay (16), were also adapted for genotyp-
ing the FXIII-A Val34Leu polymorphism. The results
obtained by the assays were compared to those
obtained by DNA sequencing on a relatively small
number (17 and 20, respectively) of samples. Both
methods seem to represent a promising alternative to
earlier assays. However, as discrimination among dif-
ferent genotypes by these methods is based on quan-
titative measures, a comparison to reference methods
on a larger number of samples is required to confirm
their specificity. The real-time PCR method presented
in this study uses FRET detection and differentiates
among genotypes on the basis of a clear difference in
the Tm of wild-type and mutant allele. With Light-
Cycler the amplification of the target DNA and deter-
mination of the genotype are performed in the same
closed capillary, limiting the risk of error and contam-
ination considerably. The LightCycler software pro-
vides a large amount of information from a single run.
The assay is specific and reproducible, and the total
analysis of 31 samples in the LightCycler takes less
than 30 min. Its specificity has been confirmed by
comparison with the most frequently used PCR-RFLP
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method and with DNA sequencing on a large number
of samples.
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